| CASSAVA SCIENCES DL-,001 |
| USA |
| Gesundheit |
| US14817C1071 / A2PGL8 |
| PX91 (Frankfurt) / SAVA (NASDAQ) |
| FRA:PX91, ETR:PX91, PX91:GR, NASDAQ:SAVA |
| - |
| https://www.cassavascienc.. |
|
Cassava Sciences Inc. is a clinical-stage biotechnology company focused on developing novel treatments for central nervous system disorders. Its primary product candidate, simufilam, is an investigational oral small molecule drug currently advancing ..
>Volltext.. |
| 69.5 Mio. EUR |
| -10.86 Mio. EUR |
| - |
| -80.84 Mio. EUR |
| -77.91 Mio. EUR |
| -1.61 EUR |
| - |
| 81.79 Mio. EUR |
| -27.62 Mio. EUR |
| 2.18 |
| - |
| -229.41% |
| - |
| - |
| - |
| - |
| CASSAVA SCIENCES |
| 08.04.26 |
|